Shafak Aluwini

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci, Ruud C. Wortel, Wendimagegn Alemayehu et al. · The Lancet Oncology · 2016 · 463 citations

Urology, Surgical Oncology, Final Efficacy Results +7

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2016 · 308 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +8

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2015 · 179 citations · Full text

Radiation Medicine, Health Sciences, Radiation Therapy +7

Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy

Linda Rossi, Rik Bijman, W. Schillemans et al. · Radiotherapy and Oncology · 2018 · 123 citations

Adaptive Radiotherapy, Geometric Modeling, Medical Imaging +13

Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors

Joost J. Nuyttens, Noëlle C. van der Voort van Zyp, J. Praag et al. · Radiotherapy and Oncology · 2012 · 105 citations

Adaptive Radiotherapy, Lung Tumors, Medical Imaging +8